Liver cancer is a high morbidity and low survival disease all over the world. Chromosomal instability is hallmark of liver cancer. Microtubule-associated serine and threonine kinase 2 (MAST2), as a microtubule associated protein, may involve in tumorous chromosomal instability and plays important roles in cell proliferation and survival. The role of MAST2 in liver cancer has not been well elucidated, which is the aim of our study. In this study, The Cancer Genome Atlas database was used to study the MAST2 mRNA expression in liver cancer, and Chi-squared tests were performed to test the correlation between clinical features and MAST2 expression. ROC curve was performed to examined the diagnostic capacity. The prognostic value of MAST2 in liver cancer was assessed through Kaplan-Meier curves as well as Cox analysis. Our results showed MAST2 was upregulated in liver cancer, and the area under the curve (AUC) was 0.925 and indicated powerful diagnostic capability. High MAST2 expression was associated with advanced clinical status such as histological type (p = 0.0059), histologic grade (p = 0.0142), stage (p = 0.0008), T classification (p = 0.0028), N classification (p = 0.0107), survival status (p = 0.0062), and poor prognosis of patients. Importantly, MAST2 was an independent risk factor for patients' prognosis after adjusting for other risk factors including stage, T classification, and residual tumor. In total, MAST2 is a potential diagnostic and prognostic biomarker of liver cancer.
. Clinical characteristics. Note: The table is partly similarity with previous publications in form [8] [9] [10] [11] .
Results
High MAST2 expression in liver cancer. A total of 373 liver cancer patients were included. The detailed characteristics, including age, gender, stage, classifications, were shown in Table 1 . Boxplots showed the differences in MAST2 expression by tumor vs adjacent normal tissue (Fig. 1A) . The results in Fig. 1A The diagnostic potential of MAST2. ROC showed the diagnostic capability of MAST2 (Fig. 2 ). The area under the curve (AUC) was 0.925 between tumor and normal tissues, which represented a powerful diagnostic capability ( Fig. 2A ). We further performed ROC analysis in subgroup of different stage, which also showed moderate to high diagnostic capability (stage I: 0.904; stage α: 0.959; stage III: 0.935; stage IV: 0.792; Fig. 2B -E). In addition, we compared the diagnostic value of MAST2 and AFP through ROC curve and found MAST2 had more diagnostic value (Fig. 2F ). Table 2 summarized the association between clinical variables and MAST2 expression. Results showed MAST2 expression was significantly associated with histological type (p = 0.0059), histologic grade (p = 0.0142), stage (p = 0.0008), T classification (p = 0.0028), N classification (p = 0.0107), and survival status (p = 0.0062).
The relationship between characteristics of patients and MAST2 expression.

MAST2 expression is associated with OS.
Proper threshold from ROC curve was cutoff to divided patients into two groups (high and low MAST2 expression). Kaplan-Meier curves were used to estimate the prognostic role of MAST2 in patients with liver cancer (Fig. 3 ). Results showed patients in MAST2 high expression group had worse OS (p < 0.0001; Fig. 3A ). Subgroup analysis further indicated expression of MAST2 significantly decreased the OS of patients in stage G1/G2 (p < 0.0001), stage I/II (p = 0.036), stage III/IV (p = 0.0011), age of young (p = 0.00017) and old (p = 0.0038) and male (p < 0.0001). Since there is data on a large number of HCC samples, we performed a subgroup analysis among HCC tumors only and found the same results, which were also verified by GSE54236 and ICGC database ( Fig. 3J -L).
Univariate analysis selected several variables correlated with OS, including stage (p = 0.001), T classification (p < 0.001), residual tumor (p = 0.003) and expression of MAST2 (p < 0.001). Together with T classification (p < 0.001) and residual tumor (p = 0.006), MAST2 expression (HR = 2.110, 95%CI: 1.467-3.035, p = 0.000) was www.nature.com/scientificreports www.nature.com/scientificreports/ independent risk factor for OS in liver cancer patients (Table 3 ) after adjusting the other variables correlated with OS (stage, T classification, and residual tumor).
Expression of MAST2 is associated with RFS. Kaplan-Meier curves indicated patients in group
of high MAST2 expression exhibited worse RFS (p = 0.0045; Fig. 4 ). Moreover, patients in stage G1/G2 (p < 0.0001), younger (p = 0.0067) and male (p = 0.00015) were more sensitive to the poor prognostic effects of MAST2 high expression ( Fig. 4 ). Subgroup analysis among HCC tumors only and found the same results ( Fig. 4J ). Univariate analysis selected that stage (p < 0.001), T classification (p < 0.001), residual tumor (p = 0.042) and expression of MAST2 (p = 0.005) were associated with RFS. In addition, multivariate analysis indicated MAST2 expression was an independent risk factor for RFS in liver cancer patients (HR = 1.517, 95%CI: 1.059-2.172, p = 0.023; Table 4 ).
Discussion
Liver cancer malignant tumor with poor prognosis, which is predominantly due to the fact that diagnosis is often made late or inaccurate 2 . To identify a new biomarker for early and accurate diagnosis has great clinical significance, many researchers have been working on developing novel biomarkers in liver cancer [8] [9] [10] [11] . In this study, we explored the diagnostic and prognostic role of MAST2 in liver cancer patients. We found that MAST2 highly expressed in liver cancer and thus, may have diagnostic value for this cancer, and its expression was correlated with histological type, histologic grade, stage, T classification, N classification, and survival status. Moreover, high MAST2 expression was associated with poor OS and RFS in patients, which suggested the prognostic role of MAST2 in liver cancer. 8-11 . www.nature.com/scientificreports www.nature.com/scientificreports/ MAST2, as a microtubule associated kinase, plays important roles in a wide range of life activities. Previous studies have reported the role of MAST2 in evolution 12 , marfan syndrome 13 , neurodegeneration 14 , rabies virus infection 15 , nonobstructive azoospermia 16 , experimental autoimmune encephalomyelitis 17 , chronic myeloid leukemia 18 and breast cancer 4 . Our studies showed the abnormal expression and prognostic effects of MAST2 in liver cancer, which broadened the field of scientific research on MAST2. www.nature.com/scientificreports www.nature.com/scientificreports/ The upregulation of MAST2 has been reported in several tumors, including esophageal cancer, pancreatic cancer, sarcomas 5 , chronic myeloid leukemia 18 and breast cancer 4 . Our results showed the overexpression of MAST2 in liver cancer. It is consistent with previous reports. We also found that the upregulation of MAST2 was distinct in different clinical features of liver cancer, such as histologic grade, stage and T classification. Moreover, the AUC of MAST2 suggest a potentially important value in tumor diagnosis and prognosis.
The effect of MAST2 in promoting tumor cell proliferation has been reported in glioblastoma. Eissmann et al. used lentiviral shRNA transduction in U87 cell line not only resulted in significantly increased apoptosis and decreased cell proliferation, but also delayed tumor growth 5 . The tumor promoting effects of MAST2 may provide a reasonable explanation for the phenomenon in our research that patients with advanced stage and worse status showed high MAST2 expression.
MAST2 plays its role through binding the C-terminal of PTEN with its PDZ domain. PTEN regulates multiple cellular processes, including polarity, migration, proliferation and metabolism 19 . PTEN, also as a tumor suppressor gene, its aberrant expression is associated with tumorigenesis and progression 20 . In our study, the poor prognosis of patients with high MAST2 expression might due to the aberrant function of PTEN.
This study firstly demonstrates the potentially diagnostic and prognostic significance of MAST2 in liver cancer patients. Moreover, the distinct expression of MAST2 and prognosis in subgroups by clinical features also provided multiple guidelines of precision therapy. However, the lower expression and AUC of MAST2 in stage IV might result from the limited sample size of stage IV patients, further studies are needed to verify these findings.
In conclusion, our study found upregulation of MAST2 in liver cancer, which corresponded with tumor progression and poor prognosis. Our findings suggest MAST2 could be a novel diagnostic and prognostic biomarker for liver cancer patients. [8] [9] [10] [11] .
Material and Methods
Data mining. The Statistical analysis. Boxplots were used to illustrate the gene expression differences between different groups and subgroups through ggplot2 22 . ROC curve was applied to examine the diagnostic capability of MAST2 
